JP2024544520A5 - - Google Patents
Info
- Publication number
- JP2024544520A5 JP2024544520A5 JP2024527384A JP2024527384A JP2024544520A5 JP 2024544520 A5 JP2024544520 A5 JP 2024544520A5 JP 2024527384 A JP2024527384 A JP 2024527384A JP 2024527384 A JP2024527384 A JP 2024527384A JP 2024544520 A5 JP2024544520 A5 JP 2024544520A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- region
- seq
- acid sequence
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263835P | 2021-11-10 | 2021-11-10 | |
| US63/263,835 | 2021-11-10 | ||
| PCT/EP2022/081225 WO2023083846A1 (en) | 2021-11-10 | 2022-11-09 | Antibody molecules and conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024544520A JP2024544520A (ja) | 2024-12-03 |
| JP2024544520A5 true JP2024544520A5 (cg-RX-API-DMAC7.html) | 2025-10-20 |
| JP7861115B2 JP7861115B2 (ja) | 2026-05-18 |
Family
ID=84387847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527384A Active JP7861115B2 (ja) | 2021-11-10 | 2022-11-09 | 抗体分子及び複合体 |
Country Status (15)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025525410A (ja) * | 2022-06-27 | 2025-08-05 | アストラゼネカ・アクチエボラーグ | 癌を治療するための上皮成長因子受容体チロシンキナーゼ阻害剤を伴う組み合わせ |
| CN122161833A (zh) * | 2023-11-15 | 2026-06-05 | 四川科伦博泰生物医药股份有限公司 | 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途 |
| AU2024380559A1 (en) | 2023-11-17 | 2026-06-04 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| IL328594A (en) | 2023-11-23 | 2026-07-01 | Velavigo Bio Inc | Binding molecule and antibody-drug conjugate and their uses |
| CN117659203B (zh) * | 2023-12-06 | 2024-08-13 | 科弈(浙江)药业科技有限公司 | 一种抗met/egfr双特异性抗体及其药物偶联物 |
| WO2025148868A1 (zh) | 2024-01-08 | 2025-07-17 | 泰励生物科技(上海)有限公司 | 一种抗体偶联药物及其用途 |
| TW202608928A (zh) * | 2024-04-30 | 2026-03-01 | 荷蘭商美勒斯公司 | 多特異性抗體藥物偶聯物 |
| TW202608927A (zh) * | 2024-04-30 | 2026-03-01 | 荷蘭商美勒斯公司 | 多特異性抗體-藥物偶聯物 |
| WO2026021476A1 (en) | 2024-07-24 | 2026-01-29 | Beone Guangzhou Biologics Manufacturing Co., Ltd. | Anti-cmet and anti-egfr multispecific antibody drug conjugates |
| CN121868507A (zh) * | 2024-10-16 | 2026-04-17 | 上海安领科生物医药有限公司 | 抗EGFR和cMET双特异性抗体的抗体药物偶联物 |
| WO2026086737A1 (en) | 2024-10-21 | 2026-04-30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Uses and methods of bispecific antibody-drug conjugates for treating tumor diseases |
| WO2026086740A1 (en) | 2024-10-21 | 2026-04-30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Use and method of bispecific antibody-drug conjugates for treating tumor diseases |
| WO2026086844A1 (zh) * | 2024-10-23 | 2026-04-30 | 正大天晴药业集团股份有限公司 | 靶向EGFR和c-Met的抗体药物偶联物 |
| WO2026098440A1 (zh) * | 2024-11-05 | 2026-05-15 | 上海齐鲁制药研究中心有限公司 | 一种双特异性抗体偶联物及其制备方法和应用 |
| WO2026124468A1 (en) * | 2024-12-10 | 2026-06-18 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Pharmaceutical combinations, their uses and therapeutic methods |
| WO2026145588A1 (en) | 2024-12-31 | 2026-07-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Use of egfr/c-met bispecific binding protein |
| WO2026151884A1 (en) | 2025-01-09 | 2026-07-16 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2026150367A1 (en) * | 2025-01-13 | 2026-07-16 | Janssen Biotech, Inc. | Bispecific anti-egfr/c-met antibody-drug conjugates |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP1521769B1 (de) | 2002-07-09 | 2015-09-09 | Dömling, Alexander | Tubulysinkonjugate |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
| BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| US8889880B2 (en) | 2010-08-06 | 2014-11-18 | Endocyte, Inc. | Processes for preparing tubulysins |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| KR102089591B1 (ko) | 2013-07-29 | 2020-03-18 | 삼성전자주식회사 | 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체 |
| CA2945318A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Tubulysin derivatives |
| JP2019500011A (ja) | 2015-11-03 | 2019-01-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用 |
| EP3630844A4 (en) | 2017-05-30 | 2021-03-03 | Chong Kun Dang Pharmaceutical Corp. | NOVEL ANTI-C-MET ANTIBODY AND USE OF IT |
-
2022
- 2022-11-09 KR KR1020247018705A patent/KR20240099430A/ko active Pending
- 2022-11-09 MX MX2024005712A patent/MX2024005712A/es unknown
- 2022-11-09 WO PCT/EP2022/081225 patent/WO2023083846A1/en not_active Ceased
- 2022-11-09 EP EP22817545.1A patent/EP4429765A1/en active Pending
- 2022-11-09 CN CN202280086269.9A patent/CN118556084A/zh active Pending
- 2022-11-09 CA CA3237211A patent/CA3237211A1/en active Pending
- 2022-11-09 US US18/053,955 patent/US12065496B2/en active Active
- 2022-11-09 IL IL312566A patent/IL312566A/en unknown
- 2022-11-09 JP JP2024527384A patent/JP7861115B2/ja active Active
- 2022-11-09 AU AU2022384597A patent/AU2022384597B2/en active Active
- 2022-11-10 AR ARP220103086A patent/AR127629A1/es unknown
- 2022-11-10 TW TW111143063A patent/TW202336037A/zh unknown
-
2024
- 2024-05-08 CL CL2024001384A patent/CL2024001384A1/es unknown
- 2024-06-07 EC ECSENADI202444371A patent/ECSP24044371A/es unknown
- 2024-06-07 CO CONC2024/0007192A patent/CO2024007192A2/es unknown
- 2024-06-25 US US18/753,316 patent/US20240360226A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7118117B2 (ja) | 抗体-薬物コンジュゲートの選択的製造方法 | |
| JP7861115B2 (ja) | 抗体分子及び複合体 | |
| CN117946274B (zh) | 抗cd73抗体及其应用 | |
| CN114106190B (zh) | 一种抗vegf/pd-l1双特异性抗体及其用途 | |
| TWI564306B (zh) | 雙特異性抗體 | |
| WO2019173832A2 (en) | Novel cytokine prodrugs | |
| ES3035714T3 (en) | Edb targeting il-12 compositions | |
| JP2020537520A5 (cg-RX-API-DMAC7.html) | ||
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| CN114981301B (zh) | Pd1和vegfr2双结合剂 | |
| CN105209493A (zh) | 用于诊断和治疗用途的her3特异性单克隆抗体 | |
| JP2020532523A (ja) | 抗egfr抗体薬物コンジュゲート(adc)及びその使用 | |
| CN115335400A (zh) | 结合整合素avb8的抗体及其用途 | |
| KR20230171465A (ko) | 항cldn4-항cd137 이중특이성 항체 | |
| CA3180188A1 (en) | Anti-flt3 antibodies and compositions | |
| CN119343378A (zh) | 靶向itga2的抗体和包含此抗体的抗体药物缀合物 | |
| CN118754989B (zh) | 一种抗her2纳米抗体及其制备方法和应用 | |
| CN117659194B (zh) | 靶向egfr的纳米抗体、药物偶联物及其用途 | |
| CN119744272A (zh) | 一种抗ror1蛋白的抗体及其缀合物 | |
| CN114773485B (zh) | 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子 | |
| CN121311503A (zh) | 靶向itga2的抗体、其抗体药物缀合物以及用途 | |
| WO2025157266A1 (zh) | 一种Nectin-4抗体及其应用 | |
| WO2026082207A1 (zh) | 抗EGFR和cMET双特异性抗体的抗体药物偶联物 | |
| CN118994393A (zh) | 一种抗fgfr2抗体及其应用 | |
| JP2024501739A (ja) | ヒトlifr抗原結合タンパク質、その製造方法及び応用 |